company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,533658.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2330223.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2863881.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2863881.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,303167.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-303167.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3167048.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,894.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3166154.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3166154.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3166154.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-9.94
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-9.94
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,318654.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q2,2012-04-01,2012-06-30,2013-08-12 07:02:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-9.94
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,533837.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2456412.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2990249.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2990249.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,361426.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-361426.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3351675.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,401.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3351274.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3351274.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3351274.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-10.31
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-10.31
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,325023.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:13:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-10.31
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1251000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2093000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3344000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3344000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,828000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-42000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-870000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4214000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-25000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4239000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4239000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4239000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-12.24
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-12.24
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,346478.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:11:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-12.24
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1172000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3100000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4272000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4272000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,108000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2545000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2653000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6925000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,4000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6921000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6921000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6921000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-19.82
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-19.82
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,349170.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:31:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-19.82
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1924000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3483000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5407000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5407000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5407000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,169000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5238000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5238000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5238000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.34
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.34
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15253704.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:19:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.34
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2398000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7338000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9736000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9736000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9736000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,46000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9690000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9690000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9690000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,7900000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,29.09
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,7900000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,29.09
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,7885921.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,29.09
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2490000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7890000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7890000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7890000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,16000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7874000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7874000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7874000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15369055.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q1,2014-01-01,2014-03-31,2014-05-12 16:11:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.51
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2726000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6528000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9254000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9254000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9255000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,17000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9238000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9238000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9238000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.6
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.6
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15399018.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q2,2014-04-01,2014-06-30,2014-08-12 16:31:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.6
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2526000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7174000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9700000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9700000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,135000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-135000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9835000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,29000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9806000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9806000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9806000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15432641.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:31:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3180000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6200000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9380000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9380000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,134000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-134000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9514000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,57000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9457000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9457000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9457000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,16400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.47
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.47
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,16374102.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.47
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4035000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7390000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11425000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11425000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,134000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-134000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11559000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,93000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11466000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11466000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11466000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.56
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.56
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20589293.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 08:33:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.56
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5253000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7209000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12462000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12462000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,135000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-135000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12597000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,202000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12395000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12395000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12395000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22465175.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:33:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5672000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7247000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12919000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12919000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,130000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-130000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13049000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,248000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12801000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12801000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12801000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.57
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.57
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22494075.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:34:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.57
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5278000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7956000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13234000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13234000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,121000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-121000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13355000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,233000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13122000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13122000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13122000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.58
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.58
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22019818.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.58
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5031000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9791000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14822000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14822000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,110000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-110000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14932000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,347000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14585000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14585000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14585000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22400000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22532031.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:33:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4633000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9698000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14331000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14331000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,99000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-99000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14430000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,395000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14035000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14035000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14035000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22600000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.62
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22600000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.62
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22541455.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:02:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.62
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4214000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13498000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17712000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17712000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,89000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-89000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17801000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,399000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17402000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17402000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17402000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22600000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.77
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22600000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.77
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22550438.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 16:32:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.77
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4404000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24881000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29285000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29285000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-298000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,298000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-28987000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,31000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-28956000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-28956000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-28956000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.29
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.29
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22544475.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.29
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5029000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35860000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40889000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-40889000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-40889000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,348000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40541000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40541000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40541000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.8
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22500000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.8
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22563152.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 16:31:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.8
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5412000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,38248000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,43660000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43660000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-43660000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,323000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-43337000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-43337000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-43337000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22600000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.92
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22600000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.92
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22591326.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 16:31:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.92
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5681000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,40056000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45737000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-45737000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-45737000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,518000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-45219000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-45219000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-45219000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,24300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.86
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24300000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.86
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,24311844.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 16:20:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.86
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5257000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33439000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38696000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38696000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,198000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-198000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38894000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1003000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37891000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37891000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-37891000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23900000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.4
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23900000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.4
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23933273.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.4
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5954000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,40940000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,46894000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-46894000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-46894000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,764000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-46130000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-46130000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-46130000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26700000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.73
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26700000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.73
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26605189.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q1,2018-01-01,2018-03-31,2018-05-02 16:31:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.73
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6956000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,39524000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,46480000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-46480000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-46480000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,750000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-45730000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-45730000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-45730000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26786796.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.71
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26786796.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.71
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26700000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:32:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.71
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9011000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,41551000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50562000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-50562000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-50562000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,651000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-49911000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-49911000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-49911000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26800000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.86
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26800000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.86
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26804026.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:30:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.86
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11176000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,49473000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,60649000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-60649000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,28000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-28000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-60677000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,638000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-60039000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-60039000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-60039000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26800000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.24
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26800000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.24
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26754308.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.24
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,145419000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,145419000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,145419000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12182000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,46308000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58490000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,86929000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,86929000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,450000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,87379000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,87379000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,87379000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26842785.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.26
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28449767.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.07
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26800000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 17:26:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.26
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13492000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,42788000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56280000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-55298000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-55298000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1077000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-54221000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-54221000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-54221000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26968818.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.01
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26968818.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.01
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:32:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.01
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1000000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18468000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,48281000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,66749000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-65768000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3996000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3996000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-69764000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1387000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-68377000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-68377000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-68377000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27100000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.52
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27100000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.52
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27171769.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:30:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.52
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,981000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,981000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,981000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,21712000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,38234000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,59946000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-58964000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4124000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4124000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-63088000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1142000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-61946000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-61946000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-61946000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27100000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.32
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27100000.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.13
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27090284.0
Esperion Therapeutics Inc,ESPR,549300OFU56UKEWVUS92,0001434868,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.32
